Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma - Summary - MDSpire

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • By

  • Marta Canelo-Vilaseca

  • Mohamad Sabbah

  • Roberta Di Blasi

  • Caterina Cristinelli

  • Anna Sureda

  • Sophie Caillat-Zucman

  • Catherine Thieblemont

  • March 27, 2025

  • 0 min

Share

Objective:

Emphasize the significance of lymphodepletion in enhancing CAR-T therapy outcomes.

Key Findings:
  • Provide context regarding the implications of the findings.
Interpretation:

Elaborate on how lymphodepletion modifies the immune landscape.

Limitations:
  • Include examples of specific trials to enhance clarity.
Conclusion:

Reiterate the need for standardization in lymphodepletion regimens.

Original Source(s)

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • by Marta Canelo-Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Sureda, Sophie Caillat-Zucman, Catherine Thieblemont

  • March 27, 2025

Related Content

Refining CAR-NK Design

Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

  • March 4, 2026

  • 2 min
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

  • by

  • February 13, 2026

  • 12 min